(Biotechnology, Medicine and Health)


BIÓPOLIS is a biotechnology company created in 2003 as a spin-off of the CSIC (Consejo Superior de Investigaciones Científicas), with the main objective of transferring quality science into the agri-food, chemical and pharmaceutical industries.   It offers contract research and production services for the agri-food, chemical and pharmaceutical industries to improve their positions and competitive advantages.

Their key skills and competences are the search for new ingredients and microbial strains, together with biology systems and metabolic engineering, followed by innovative pre-clinical and technological validation models.

They make the entire journey from proof of concept to large-scale production, covering a wide range of possibilities for collaboration with the industrial sector.  As a final step in their value chain, they offer the design, optimisation and over-production of metabolites and microorganisms.


The information contained in this business data sheep has been provided by the company and the University of Valencia Science Park Foundation (FPCUV) is not responsible for its content.

Download Impulse to Business Development Programme (PIDE)'s file

Technology offer

Technical Specifications

​​​​​​Microbiology, molecular biology, fermentation and engineering applied to the development of strains and bio-processes:

  • Access to databases and specialised computer resources
  • Isolation of new strains;  the selection and validation of strains of culture type collections.   Improvement led by mutagenesis and genetic engineering.
  • Development and optimisation of processes, selection of culture media, and optimisation of raw material costs
  • Availability of equipment for extraction and fine purification:  sonication, pressure homogenisation, liquid-liquid extraction, solid-liquid, ultra-filtration, preparative chromatographic purification
  • Tuning of analysis methods.  Specific stains, spectro-photometric or chemi-luminescent analysis, immunoreactivity, gas and liquid chromatography for detection and quantification of biochemical compounds.

High performance in vitro screening and “in vivo” models, that offer the possibility to identify the molecule responsible for the functionality, as well as the metabolic process and/or target genes upon which it acts.

  • Evaluation of the biological activity of effective functional ingredients against health disorders, such as aging, obesity, diabetes, cardio-vascular diseases, hypertension, neuro-degenerative diseases (Alzheimer's), pathogen infections, toxicity and immunity.
  • “In vitro” and “in vivo” validation assays:
    • “In vitro”: Exploration of enzymatic activity for a wide range of applications.
    • “In vivo”:  Saccharomyces cerevisiae, Caenorhabditis elegans, Medaka fish (Oryzias latipes), murine models (rat/mouse)
    • “Ex vivo”:  Cultivation of living cells and tissues from an organism with the aim of detecting the biological activity of a specific compound, such as a complement or replacement of existing “in vivo” models.


Benefits of Technology


  • Novel high-throughput scrutiny techniques in “in vivo” models (C. elegans).
  • Rapid detection of functional ingredients.
  • Omic technologies:  genomics, transcriptomics, metabolomics and nutrigenomics.
  • Availability of massive sequencing technology through affiliate company Lifesequencing SL (
  • Miniaturised fermentation equipment with control of environmental variables for design of experiments, clonal selection, optimisation of bio-reactions.
  • In-house scaling of the fermentation and purification process (up to 9,000 L). Production of pilot lots for validation.


  • Scaling of functional ingredient production
  • Industrial production.
  • Support in Technology Transfer.
  • Inter-disciplinary staff with extensive experience.
  • From proof of concept to long-term developments.
Technology Applications
  • Functional foods, nutritional supplements, probiotics, starters, proteins, vaccines, functional feeds, nutria-cosmetics, bio-technological processes, pest bio-control, expression of recombinant proteins in bacterial and eukaryotic systems, obtaining and development of cell lines and monoclonal antibodies.
  • Design, development and optimisation of enzymatic or microbial catalysis processes.
  • Characterisation, validation and selection of high-yield industrial strains, recovery of waste and industrial by-products.
  • Strain design and processes to obtain bio-fuels.
  • Obtaining bacterial polymers (PHA), and APIs.
Sectors to which company is directed
  • Human and animal foods.
  • Nutritional supplements.
  • Energy, agricultural, pharmaceutical and cosmetic sectors.
  • Fine chemistry

BIOPOLIS company news

Biotech company ADM Biópolis increases its turnover by 87% in 2022 to almost 13 million and enters into profitRead more »
ADM Biópolis maintains its commitment to the Science Park in the line of research workRead more »
ADM collaborates in a trial to test the effects of probiotic supplements in patients with COVID-19Read more »
A public-private partnership in the Science Park demonstrates the antioxidant potential of bacteria extracted from solar panelsRead more »
The nutraceutical industry rewards Daniel Ramón for his "outstanding contribution to the development of food science and biotechnology"Read more »
A research in C. elegans shows that the intake of a tangerine carotenoid reduces the body fat by 30%Read more »

Contact information Phone: (+34) 963 160 299